Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Comparative effectiveness and toxicity of CAR-T therapy versus blinatumomab in adult B-cell acute lymphoblastic leukemia: A real-world propensity-matched analysis.2026
2. 2Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database2025 · 1 citations
3. 3A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system2025
4. 4Adverse Events of CD19- and BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy: An Analysis of the FDA Adverse Events Database2026
5. 5Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies: A Real-World FAERS Pharmacovigilance Study2026 · 1 citations